Neuroendocrinology Archive

Mixed Metabolic Profiles Found in Acromegaly Remission

Some cardiovascular risk factors and adiposity increased during acromegaly remission.

Long-Acting Release Signifor Effective in Acromegaly Trial

Long-Acting Release Signifor Effective in Acromegaly Trial

Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

Sign Up for Free e-Newsletters

CME Focus